IKNA — Ikena Oncology Income Statement
0.000.00%
Last trade - 00:00
- $83.49m
- -$61.93m
- $9.16m
- 51
- 25
- 62
- 43
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 13.8 | 9.19 | 31 | 15.6 | 9.16 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 32.2 | 53.7 | 65.1 | 86.5 | 84.6 |
Operating Profit | -18.5 | -44.5 | -34.1 | -70.9 | -75.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -16.8 | -44.3 | -34.1 | -68.8 | -68.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -16.8 | -44.3 | -34.1 | -68.8 | -68.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -16.8 | -44.3 | -34.1 | -68.8 | -68.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -16.8 | -44.3 | -34.1 | -68.8 | -68.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.486 | -1.28 | -0.948 | -1.9 | -1.61 |
Dividends per Share |